RESUMEN

En años recientes se ha descrito de manera minuciosa, la relevancia del papel de la proteína HIF-1 alfa en diversos procesos patológicos y biológicos como son la carcinogénesis y la embriogénesis. Nuestro grupo de trabajo está interesado en esta proteína y su relación con el desarrollo de la fibrosis pulmonar idiopática (FPI), debido a que se ha observado que juega un importante papel en la génesis de la fibrosis renal, en donde se ha reportado que regula la transición epitelio-mesénquima, evento que se ha asociado con el desarrollo de la FPI. Por otro lado, los análisis de expresión génica en la FPI indican que los genes regulados por la hipoxia se encuentran alterados, lo cual sugiere un papel primario de HIF-1 alfa en el desarrollo de la FPI, así como la posibilidad de que la inducción de la síntesis de esta proteína sea un evento temprano en su patogénesis. Debido a su función y a los estudios actuales de HIF-1 alfa en relación con su participación en la fibrosis renal, así como en distintos tipos de cáncer, se realiza esta revisión de HIF-1 alfa y su participación en la FPI.

PALABRAS CLAVE

FPI, HIF-1α, cáncer.

REFERENCIAS

1. Selman M, King TE, Pardo A, and; American Thoracic Society; European Respiratory Society; American College of Chest Physicians. Idiopathic pulmonary Fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-151.

2. Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008;3:8.

3. DHEW publication [NIH]. Respiratory Diseases Task Force: report on problems, research, approaches, and needs. October, 1972:73-432.

4. Nadrous HF, Myers JL, Decker PA, Ryu JH. Idiopathic pulmonary fibrosis in patients younger than 50 years. Mayo Clin Proc 2005;80:37-40.

5. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174:810-816.

6. Olson AL, Swigris JJ, Lezotte DC, Norris JM, Wilson CG, Brown KK. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 2007;176:277-284.

7. Andersson-Sjöland A, de Alba CG, Nihlberg K, et ál. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol 2008;40:2129-2140.

8. Selman M, Pardo A. Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder. Respir Res 2002;3:3.

9. Pardo A, Selman M. Molecular mechanisms of pulmonary fibrosis. Front Biosci 2002;7:d1743-d1761.

10. Kolyada AY, Tighiouart H, Perianayam MC, Liangos O, Madias NE, Jaber BL. A genetic variant of hypoxia-inducible factor-1alpha is associated with adverse outcomes in acute kidney injury. Kidney Int 2009;75:1322-1329.

11. Olman MA, White KE, Ware LB, et ál. Pulmonary edema fluid from patients with early lung injury stimulates fibroblast proliferation through IL-1 beta-induced IL-6 expression. J Immunol 2004;172:2668-2677.

12. Björnheden T, Levin M, Evaldsson M, Wiklund O. Evidence of hypoxic areas within the arterial wall in vivo. Arterioscler Thromb Vasc Biol 1999;19:870-876.

13. Kimura K, Iwano M. Molecular mechanisms of tissue fibrosis. Nihon Rinsho Meneki Gakkai Kaishi 2009;32:160-167.

14. Jain M, Sznajder JI. Effects of hypoxia on the alveolar epithelium. Proc Am Thorac Soc 2005;2:202-205.

15. Ruivo S, Viana P, Martins C, Baeta C. Effects of aging on lung function. A comparison of lung function in healthy adults and the elderly. Rev Port Pneumol 2009;15:629-653.

16. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003;112:1776-1784.

17. Görlach A. Regulation of HIF-1 alpha at the transcriptional level. Curr Pharm Des 2009;15:3844-3852.

18. Kolyada AY, Tighiouart H, Perianayagam MC, Liangos O, Medias NE, Jaber BL. A genetic variant of hypoxia-inducible factor-1alpha is associated with adverse outcomes in acute kidney injury. Kidney Int 2009;75:1322-1329.

19. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-732.

20. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000;88:1474-1480.

21. Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, Simon MC. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 1997;386:403-407.

22. Kozak KR, Abbott B, Hankinson O. ARNT-deficient mice and placental differentiation. Dev Biol 1997;191:297-305.

23. Percy MJ, Mooney SM, McMullin MF, Flores A, Lappin TR, Lee FS. A common polymorphism in the oxygen-dependent degradation (ODD) domain of hypoxia inducible factor-1a (HIF-1a) does not impair Pro-564 hydroxylation. Mol Cancer 2003;2:31.

24. Deshmane SL, Mukerjee R, Fan S, et ál. Activation of the oxidative stress pathway by HIV-1 Vpr leads to induction of hypoxia-inducible factor 1alpha expression. J Biol Chem 2009;284:11364-11373.

25. Clerici C, Planès C. Gene regulation in the adaptive process to hypoxia in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2009;296:L267-L274.

26. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 2001;20:5197-5206.

27. Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE. Hypoxia-inducible nuclear factors bind to an enhancer element located 3’ to the human erythropoietin gene. Proc Natl Acad Sci USA 1991;88:5680-5684.

28. Semenza GL, Rue EA, Iyer NV, Pang MG, Kearns WG. Assignment of the hypoxia-inducible factor 1alpha gene to a region of conserved synteny on mouse chromosome 12 and human chromosome 14q. Genomics 1996; 34:437-439.

29. Iyer NV, Leung SW, Semenza GL. The human hypoxia-inducible factor 1alpha gene: HIF1A structure and evolutionary conservation. Genomics 1998;52:159-165.

30. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995;92:5510-5514.

31. Jiang BH, Zheng JZ, Leung SW, Roe R, Semenza GL. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J Biol Chem 1997;272:19253-19260.

32. Kallio PJ, Okamoto K, O ‘Brien S, et ál. Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha. EMBO J 1998;17:6573-6586.

33. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998;95:7987-7992.

34. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 2001;20:5197-5206.

35. Rannala B. Finding genes influencing susceptibility to complex diseases in the post-genome era. Am J Pharmacogenomics 2001;1:203-221.

36. Yamada N, Horikawa Y, Oda N, et ál. Genetic variation in the hypoxia-inducible factor-1alpha gene is associated with type 2 diabetes in Japanese. J Clin Endocrinol Metab 2005;90:5841-5847.

37. Percy MJ, McMullin MF, Lappin TR. Sequence analysis of the 3’ hypoxia-responsive element of the human erythropoietin gene in patients with erythrocytosis. Biochem Mol Med 1997;62:132-134.

38. Hebert C, Norris K, Parashar P, Ord RA, Nikitakis NG, Sauk JJ. Hypoxia-inducible factor-1alpha polymorphisms and TSC1/2 mutations are complementary in head and neck cancers. Mol Cancer 2006;5:3.

39. Konac E, Onen HI, Metindir J, Alp E, Biri AA, Ekmekci A. An investigation of relationships between hypoxia-inducible factor-1alpha gene polymorphisms and ovarian, cervical and endometrial cancers. Cancer Detect Prev 2007; 31:102-109.

40. Koukourakis MI, Papazoglou D, Giatromanolaki A, et ál. C2028T polymorphism in exon 12 and dinucleotide repeat polymorphism in intron 13 of the HIF-1alpha gene define HIF-1alpha protein expression in non-small cell lung cancer. Lung Cancer 2006;53:257-262.

41. Hong JM, Kim TH, Chae SC, et ál. Association study of hypoxia inducible factor 1alpha (HIF1alpha) with osteonecrosis of femoral head in a Korean population. Osteoarthritis Cartilage 2007;15:688-694.

42. Clifford SC, Astuti D, Hooper L, Maxwell PH, Ratcliffe PJ, Maher ER. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma. Oncogene 2001;20:5067-5074.

43. Bos R, Zhong H, Hanrahan CF, et ál. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 2001;93:309-314.

44. Koukourakis MI, Giatromanolaki A, Skarlatos J, et ál. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 2001;61:1830-1832.

45. Fu XS, Choi E, Bubley GJ, Balk SP. Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate 2005;63:215-221.

46. Ollerenshaw M, Page T, Hammonds J, Demaine A. Polymorphisms in the hypoxia inducible factor-1 alpha gene (HIF1A) are associated with the renal cell carcinoma phenotype. Cancer Genet Cytogenet 2004;153:122-126.

47. Lee JY, Choi JY, Lee KM, et ál. Rare variant of hypoxia-inducible factor-1alpha (HIF-1A) and breast cancer risk in Korean women. Clin Chim Acta 2008;389: 167-170.

48. Resar JR, Roguin A, Voner J, et ál. Hypoxia-inducible factor 1alpha polymorphism and coronary collaterals in patients with ischemic heart disease. Chest 2005;128: 787-791.

49. Tzouvelekis A, Harokopos V, Paparountas T, et ál. Comparative expression profiling in pulmonary fibrosis suggests a role of hypoxia-inducible factor-1alpha in disease pathogenesis. Am J Respir Crit Care Med 2007;176: 1108-1119.

50. Krick S, Eul BG, Hänze J, et ál. Role of hypoxia-inducible factor-1alpha in hypoxia-induced apoptosis of primary alveolar epithelial type II cells. Am J Respir Cell Mol Biol 2005;32:395-403.

51. Shahar I, Fireman E, Topilsky M, et ál. Effect of endothelin-1 on alpha-smooth muscle actin expression and on alveolar fibroblasts proliferation in interstitial lung diseases. Int J Immunopharmacol 1999;21:759-775.

52. Madjdpour C, Jewell UR, Kneller S, et ál. Decreased alveolar oxygen induces lung inflammation. Am J Physiol Lung Cell Mol Physiol 2003;284:L360-L367.

53. Orphanides C, Fine LG, Norman JT. Hypoxia stimulates proximal tubular cell matrix production via a TGF-beta1-independent mechanism. Kidney Int 1997; 52:637-647.

54. Kietzmann T, Roth U, Jungermann K. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood 1999;94:4177-4185.

55. Sánchez-Elsner T, Botella LM, Velasco B, Corbí A, Attisano L, Bernabéu C. Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J Biol Chem 2001;276:38527-38535.

56. Sánchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabéu C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 2002;277:43799-43808.

57. Sánchez-Elsner T, Ramírez JR, Sanz-Rodríguez F, Varela E, Bernabéu C, Botella LM. A cross-talk between hypoxia and TGF-beta orchestrates erythropoietin gene regulation through SP1 and Smads. J Mol Biol 2004; 336:9-24.

58. Alder JK, Chen JJ, Lancaster L, et ál. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA 2008;105:13051-13056.

59. Loh SA, Chang EI, Galvez MG, et ál. SDF-1alpha expression during wound healing in the aged is HIF dependent. Plast Reconstr Surg 2009;123(2 Suppl):65S-75S.

60. Hoenig MR, Bianchi C, Rosenzweig A, Sellke FW. Decreased vascular repair and neovascularization with ageing: mechanisms and clinical relevance with an emphasis on hypoxia-inducible factor-1. Curr Mol Med 2008;8:754-767.